AntriaBio

Developing Innovative Therapies for Patients with Diabetes and Metabolic Diseases

Lead product candidate AB101 is a recombinant human basal insulin formulated for once-weekly injection with the potential to significantly advance the treatment paradigm for insulin replacement therapy.

Learn More

Investor Relations